Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate Cancer Risk Factors

Prostate Cancer Screening

Prostate Cancer Symptoms

Prostate cancer complications

Prostate Cancer Diagnosis

Prostate Cancer Staging

Prostate Cancer Treatment

Radiation therapy for prostate cancer

Life after prostate cancer treatment

Prostate cancer prevention

See more featured articles »

Survival rates of prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

Prostate Cancer Epidemiology

Prostate Cancer Research

Prostate Cancer Partin Tables

Prostate Cancer and Genetics

Prostate Cancer and Diet

Rectal Examination for Prostate Cancer

Cryosurgery for prostate cancer

Hormonal therapy for prostate cancer

Prostate cancer alternative and complementary therapies

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

The International Prostate Symptoms Score (IPSS)

Types of PSA Test

What is the PSA Test?

Prostate Biopsy

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Differentiating between prostate cancer and prostate enlargement

Choosing the best treatment of prostate cancer - by stage

What is the PCA3 Test?

What is the Gleason Score?

What is Prostatectomy?

What is Prostatitis?

Causes of prostatitis

Prostatitis symptoms

Diagnosis of prostatitis

Treatment of prostatitis

What is TURP?

What is medical castration?

What is benign prostatic hyperplasia?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Symptoms of Benign Prostatic Hyperplasia (BHP)

Causes of benign prostatic hyperplasia

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer and Exercise

Prostate Cancer Epidemiology Worldwide

Prostate Cancer Cell Dormancy and Activation

Single Nucleotide Polymorphisms and Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Brachytherapy for Prostate Cancer

Latest Prostate Cancer News and Research

UCLA, UCSF obtain FDA approval for PSMA PET imaging in men with prostate cancer

The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new imaging technique for prostate cancer that locates cancer lesions in the pelvic area and other parts of the body to which the tumors have migrated.

2 Dec 2020

First PSMA-targeted PET imaging drug approved for men with prostate cancer

Today, the U.S. Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) - the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.

1 Dec 2020

Experimental drug can reverse age-related memory decline in mice

Just a few doses of an experimental drug can reverse age-related declines in memory and mental flexibility in mice, according to a new study by UC San Francisco scientists.

1 Dec 2020

Cost of prostate cancer treatment can be a major source of stress for men, their families

For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology®, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

1 Dec 2020

Researchers find substantial regional variation in use of genomic testing for prostate cancer

Gene-expression testing provides better estimates of cancer aggressiveness and assist in treatment decision making for men with prostate cancer.

30 Nov 2020

World’s largest proteomics centre accelerates biomarker discoveries to improve people’s lives

Opened in 2016, Manchester’s Stoller Biomarker Discovery Centre (SBDC) is a globally renowned, multi-million-pound precision medicine research facility.

From Stoller Biomarker Discovery Centre 30 Nov 2020

Medical mistrust can make African Americans to regret their choice of treatment for prostate cancer

Medical mistrust is one reason why African American patients are more likely to have regrets about their choice of treatment for prostate cancer.

25 Nov 2020

Study assesses impact of social needs on African American cancer survivors

Social needs--such as food and economic insecurity, poor housing and neighborhood conditions, and lack of access to transportation--were common in a group of African American cancer survivors in Detroit, and they were associated with lower health-related quality of life (HRQOL).

23 Nov 2020

New findings could pave the way for more effective, safer and cheaper gene therapy

In a promising advance for affordable, personalized medicine, researchers have used metal-organic frameworks to successfully deliver the genetic snipping tool CRISPR/Cas9 into human cancer cells.

20 Nov 2020

Study identifies enzyme vital to the metastatic growth of prostate cancer cells

While prostate cancer originates within the prostate, metastasis, or the spread of a tumor from the site of origin to other organs, remains a leading cause of death among people with the disease.

19 Nov 2020

CRYM protein counteracts the growth of prostate tumors

Prostate cancer is caused by elevated hormone levels, and tumors are generally treated using hormone therapy. However, after some time, tumor growth is no longer dependent on hormones, which results in resistance to treatment. As a result, new types of treatments are urgently needed.

18 Nov 2020

Negative biopsies during active surveillance for prostate cancer are associated with long-term outcomes

Can early-stage prostate cancer "vanish" during follow-up? More likely the cancer is just "hidden"--either way, negative biopsies during active surveillance for prostate cancer are associated with excellent long-term outcomes, reports a study in The Journal of Urology®.

18 Nov 2020

Researchers explain why COVID-19 infects older people and spares younger children

Researchers at Vanderbilt University Medical Center (VUMC) and their colleagues have determined a key factor as to why COVID-19 appears to infect and sicken adults and older people preferentially while seeming to spare younger children.

16 Nov 2020

Men and women may require different brain tumor therapy, study finds

The current study shows that the sex differences in the tumor phenotype vary with the effect of the enhancer regulatory molecule bound to Brd4 on the course of stem cell-like differentiation in male and female GBM cells. Inhibition of Brd4 by genetic and pharmacological factors also varies in males and females, both in vivo and in vitro.

11 Nov 2020

Grants give military veterans better access to cancer clinical trials

SWOG Cancer Research Network and its charity, The Hope Foundation for Cancer Research, announce the award of two grants designed to give military veterans better access to cancer clinical trials.

11 Nov 2020

Gene signature may help develop new therapies against advanced prostate cancer

Researchers have identified a genetic signature in localized prostate cancer that can predict whether the cancer is likely to spread, or metastasize, early in the course of the disease and whether it will respond to anti-androgen therapy, a common treatment for advanced disease.

11 Nov 2020

Active surveillance is a safe and viable option for men with low-risk prostate cancer

Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in The Journal of Urology®, an Official Journal of the American Urological Association.

9 Nov 2020